1) Chan JKC, Quintanilla-Martinez L, Ferry JA, et al.:Extranodal NK/T-cell lymphoma, nasal type. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC, Lyon, 2008, pp285-288
2) Oshima K:Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 139:532-544, 2007
3) Suzuki R:Leukemia and lymphoma of natural killer cells. J Clin Exp Hematopathol 45:51-70, 2005
4) 鈴宮淳司, 大島孝一:NK細胞リンパ腫:病因と臨床像. 臨床血液 49:545-552, 2008
5) Suzuki R, Yamamoto K, Seto M, et al.:CD7+and CD56+ myeloid/natural killer cell precursor acute leukemia:a distinct hematolymphoid disease entity. Blood 90:2417-2428, 1997
9) Sanchez MJ, Muench MO, Roncarolo MG, et al.:Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med 180:569-576, 1994
10) Ng CS, Chan JK, Lo ST:Expression of natural killer cell markers in non-Hodgkin's lymphomas. Hum Pathol 18:1257-1262, 1987
11) 大野敏之, 塚田哲也, 川上惠基ほか:Natural killer 細胞由来の鼻腔原発悪性リンパ腫の1例. 臨床血液 31:487-491, 1990
12) Suzumiya J, Takeshita M, Kimura N, et al.:Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood 83:2255-2260, 1994
13) Kaneko T, Fukuda J, Yoshihara T, et al.:Nasal natural killer (NK) cell lymphoma:report of a case with activated NK cells containing Epstein-Barr virus and expressing CD21 antigen, and comparative studies of their phenotype and cytotoxicity with normal NK cells. Br J Haematol 91:355-361, 1995
15) Harabuchi Y, Yamanaka N, Kataura A, et al.:Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335:128-130, 1990
16) Jaffe ES, Chan JK, Su IJ, et al.:Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg J Pathol 20:103-111, 1996
17) The World Health Organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 50:696-702, 2000
18) Ko YH, Kim CW Park CS, et al.:REAL classification of malignant lymphomas in the Republic of Korea:incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 83:806-812, 1998
20) Vose J, Armitage J, Weisenburger D, et al.:International peripheral T-cell and naturall killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
21) Kwong YL, Chan AC, Liang RH:Natural killer cell lymphoma/leukemia:pathology and treatment. Hematol Oncol 15:71-79, 1997
22) Wong KE Chan JK, Cheung MM, et al.:Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Ann J Clin Pathol 115:266-270, 2001
24) Nakashima Y, Tagawa H, Suzuki R, et al.:Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia:different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/Tcell lymphoma, nasal type. Genes Chromosomes Cancer 44:247-255, 2005
26) Liu Q, Ohshima K, Sumie A, et al.:Nasal CD56 positive small round cell tumors. Differential diagnosis of hematological, neurogenic, and myogenic neoplasms. Virchows Arch 438:271-279, 2001
28) Tsukamoto N, Kojima M, Hasegawa M, et al.:The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-pet with 67gallium scintigraphy in the evaluation of lymphoma:relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652-659, 2007
29) Miller TP, Dahlberg S, Cassady JR, et al.:Chemotherapy alone compared with chemotherapy plus radiotherapy for localize d intermediate-and high-grade non-Hodgkin's lymphoma. N Engl Med 339:21-26, 1998
30) Yamaguchi M, Ogawa S, Nomoto Y, et al.:Treatment outcome of nasal NK-cell lymphoma:A report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematopathol 41:93-99, 2001
32) Egashira M, Kawamata N, Sugimoto K, et al.:P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93:599-606, 1999
34) Ribrag V, Ell Hajj M, Janot F, et al.:Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 15:1123-1126, 2001
35) Li YX, Yao B, Jin J, et al.:Radiotherapy as primary treatment for stage I E and II E nasal natural killer/T-cell lymphoma. J Clin Oncol 24:181-189, 2006
36) Yamaguchi M, Oguchi M, Tobinai K, et al.:Phase I/II study of concurrent chemoradiotherapy for newly-diagnosed, localized nasal NK/T-cell lymphoma:results of a phase I portion of JCOG0211-DI. Blood 106:2685, 2005
38) Lee J, Suh C, Park YH, et al.:Extranodal natural killer T-cell lymphoma, nasal-type:aprognostic model from a retrospec-tive multicenter study. J Clin Oncol 24:612-618, 2006
40) Yong W, Zheng W Zhang Y, et al.:L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/ NK-cell lymphoma. Int J Hematol 78:163-167, 2003
41) Yong W Zheng W Zhu J, et al.:L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 88:647-652, 2009
42) Jaccard A, Petit B, Girault S, et al.:L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 20:110-116, 2009
44) Kim K, Ryu K, Ko Y, et al.:Effects of nuclear factor-κB inhibitors and its implication on natural killer T-cell lymphoma cells. Br J Hematol 131:59-66, 2005
46) Au WY, Lie AK, Liang R, et al.:Autologous stem cell transplantation for nasal NK/T-cell lymphoma:a progress report on its value. Ann Oncol 14:1673-1676, 2003
47) Kim HJ, Bang SM, Lee J, et al.:High-dose chemotherapy with autologous stem cell transplantation in extranod al NK/Tcell lymphoma:a retrospective comparison with non-trans-plantation cases. Bone Marrow Transplant 37:819-824, 2006
50) Makita M, Maeda Y, Takenaka K, et al.:Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions. Int J Hematol 76:94-97, 2002
51) Kim TM, Park YH, Lee SY, et al.:Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I E/II E extranodal NK/T-cell lymphoma, nasal type. Blood 106:3785-3790, 2005
52) Lin CW, Chen YH, Chuang YC, et al.:CD94 transcripts simply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. Btood 102:2623-2631, 2003
53) Takahara M, Kishibe K, Bandoh N, et al.:P53, N-and K-Ras, and β-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum Pathol 35:86-95, 2004
54) Huang WT, Chang KC, Huang GC, et al.:Bone marrow that is positive for Epstein-Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica 90:1063-1069, 2005